

Congenital Heart Disease and Pregnancy



Matthias Greutmann, MD Adult Congenital Heart Disease Program University Hospital Zurich, Switzerland matthias.greutmann@usz.ch







Age 9: Mechanical tricuspid valve replacement


Postop AV-block→ Pacemaker





Age 25: Planned pregnancy • Warfarin → LMWH Dalteparin <u>fixed dose</u> 200U/kg = 10,000 U s.c. OD

12 weeks gestation: Mean ∆p across valve: 10 → 16 mmHg


Hemodynamic changes







Mean ∆p: 15 mmHg



What went wrong

• Ris a table ation • Correeling Pregaticy management Early detection of complications


Objectives

- Scope of the problem
- Risk stratification
- Counselling
- Management & Care


Objectives

- Scope of the problem
- Risk stratification
- Counselling
- Management & Care


Deaths / 100,000 maternities 2006-2008



Cardiac deaths 1985 - 2008




Cardiac deaths 1985 - 2008







Improved Survival - complex congenital heart disease -



Complex CHD



Marelli, Circ 2007




Objectives


- Scope of the problem
- Risk stratification
- Counselling
- Management & Care

Risk stratification - global

Heart failure
Other non-fatal cardiovascular complications
Death




Risks – lesion specific



Drenthen, JACC 2007

Risks – lesion specific



Arrhythmia
 Heart Failure
 Stroke / death

Drenthen, JACC 2007

Risk stratificationModified WHO classificationWHO IWHO IIWHO IVWHO IWHO IIWHO IVNo RiskSmall RiskSignifcant RiskContraindicat.

Risk stratification MODIFIED WHO CLASSIFICATION WHO I WHO III WHO IV No Risk Small Risk Signifcant Risk Contraindicat. • Mild PS • Mild PS

Small VSD

•

Risk stratification Modified WHO classification

WHO III

No Risk Small Risk Signifcant Risk

WHO II

Mild PS

•

Small VSD

WHO I

Severe AS, MS

WHO IV

....


- PHT
- Marfan root > 45
- LVEF < 30
- NYHA III or IV
- S/p PpCMP & LVEF < 55%

Risk stratification Modified WHO classification WHO I WHO II WHO III WHO IV No Risk Small Risk Signifcant Risk • Mild PS Mechanical valve Severe AS, MS ASD Mild LVEF Small VSD Fontan PHT Systemic RV Marfan – root > 45 • LVEF < 30 • NYHA III or IV Individual risk


stratification!

•


S/p PpCMP & LVEF < 55%




Pre-Pregnancy!




Type of CHD
Severity
Associated lesions



Type of CHD
 Severity
 Associated lesions
 Cardiac function



Type of CHD > Severity Associated lesions Cardiac function Hemodynamics ➢i.e. pulmonary HTN Residual shunts





- Exercise capacity
- Comorbidities
- Previous complications
 - Risk for twin pregnancy (IVF!)
 - **Risk for preeclampsia**

Fetal risk: Risk factors

- NYHA class >II or cyanosis
- Left heart obstruction
- Smoking during pregnancy
- Multiple gestation
- Oral anticoagulants
- Mechanical valve prosthesis

Siu, Circ 2001 Khairy, Circ 2006 Drenthen, EHJ 2010

Fetal risk: Medication


ACE-inhibitors, ARB Statins

• • • •

Case: 34 years



Case: 34 years



Most dangerous – unknown HD!

Objectives

- Scope of the problem
- Risk stratification
- Counselling
- Management & Care

		Contraindication to pregnancy	
		No	Yes
Patient being told to avoid pregnancy	No		
	Yes		

Kovacs AK, JACC 2008

		Contraindication to pregnancy	
		No	Yes
Patient being told to avoid pregnancy	No	69%	
	Yes		8%

Kovacs AK, JACC 2008



Kovacs AK, JACC 2008


 Maternal r Type of complications During pre Managable Long-term Avoidable Fetal risks Recurrence Fatal / irreversible Preterm d


Objectives

- Scope of the problem
- Risk stratification
- Counselling
- Management & Care

Management & Care: Team! Obstetrician

Cardiologist





Anesthetist




Hematologist, ICU-specialists, ...

Pregnant

woman

Management & Care: Serial BNP



Controls: → 0% BNP > 100

BNP < 100: → 100% neg. predictive for cardiovascular complications

1st Trimester 3rd Trimester

Tanous, JACC 2010

Management & Care


Patient education!

Management plan

> Available!

- Clear & detailed enough!
- Drugs that need to be available

Complex anatomy: Drawing!



Ressources



European Heart Journal doi:10.1093/eurheartj/ehr218


ESC GUIDELINES

ESC Guidelines on the management of cardiovascular diseases during pregnancy

The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)

Endorsed by the European Society of Gynecology (ESG), the Association for European Paediatric Cardiology (AEPC), and the German Society for Gender Medicine (DGesGM)

www.heartdiseaseandpregnancy.com



Heart Disease and Pregnancy

Edited by Philip J Steer, Michael A Gatzoulis and Philip Baker



RCOG Press

Royal College of Obstetricians and Gynaecologists 27 Sussex Place, Regent's Park, London NW1 4RG

www.rcog.org.uk



Thank you





Matthias Greutmann, MD Adult Congenital Heart Disease Program University Hospital Zurich, Switzerland matthias.greutmann@usz.ch

